Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Mercatello, A.
Right arrow Articles by Despaux, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mercatello, A.
Right arrow Articles by Despaux, E.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (1996) 37, 1017-1021
© 1996 The British Society for Antimicrobial Chemotherapy


brief-report

Concentration of teicoplanin in the serum of adults with end stage chronic renal failure undergoing treatment for infection

A. Mercatelloa, K. Jaberb, D. Hillaire-Buysc, B. Coronela, J. Berlandb and E. Despauxd

aDepartment of Nephrology, H;ôpital Ed. Herriot 69437Lyon Cedex 03, France bDepartment of Haemodialysis, H;ôpital Ste Marguerite 13009 Marseille, France cPharmacology Department, H;ôpital Saint-Eloi 34295 Montpellier, France dBacteriological Service, H;ôpital Saint-Eloi 34295 Montpellier, France

Received 11 July 1995; returned 21 September 1995; accepted 6 December 1995


We examined the adequacy of the following schedule for the administration of iv teicoplanin to patients with chronic renal failure: three doses of 6 mg/kg at 12 h intervals, a fourth dose 24 h later and then subsequent doses every 72 h. Eight infected patients undergoing dialysis were investigated, with serum antibiotic concentrations measured ten minutes before and one hour after administration. Mean trough concentrations were 6.9±3.1 mg/L on day two, 9.8±4.4 mg/L (day three), 9.2±4.8 mg/L (day six), 10.9±5.5 mg/L (day nine), 12.1±6.1 mg/L (day 12) and 14.8±8.0 mg/L (day 15). The proposed schedule achieved adequate trough serum teicoplanin concentrations by 48 h in six out of eight patients examined. The dosage regimen was well tolerated.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.